About KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc (KALV) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet medical need. The company’s lead product candidate is KVD900, an oral plasma kallikrein inhibitor being developed for the treatment of hereditary angioedema (HAE). HAE is a rare, genetic disorder characterized by recurrent episodes of swelling in various parts of the body, including the skin, gastrointestinal tract, and airway. KVD900 has the potential to provide a convenient, effective treatment option for patients with HAE, who currently have limited therapeutic options.

KalVista Pharmaceuticals Inc has a market capitalization of $XXX.XX million, indicating the total market value of the company's outstanding shares of stock. The stock price history of KALV shows the historical prices and trading volume of KALV shares over a certain period of time. Investors can analyze this information to identify trends and patterns in the stock's performance. KALV's 52-week range refers to the lowest and highest prices at which KALV shares have traded over the past year. This range provides investors with an idea of the stock's volatility and potential price movement. Additionally, KALV's day range indicates the range of prices at which KALV shares have traded during a single trading session. This information can be useful for day traders looking to enter or exit positions at specific price levels.